Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice

• Main Authors: Ya Suo (Author), Meng Yuan (Author), Hongmin Li (Author), Yue Zhang (Author), Ying Li (Author), Huaying Fu (Author), Fei Han (Author), Changhui Ma (Author), Yuanyuan Wang (Author), Qiankun Bao (Author), Guangping Li (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

LCZ696 (sacubitril/valsartan) is an angiotensin receptor-neprilysin inhibitor and has shown beneficial effects in patients with heart failure. However, whether LCZ696 protects against left atrial (LA) and LA appendage (LAA) dysfunction is still unclear. The present study aimed to assess the efficacy...